<PAGE> 1
As filed with the Securities and Exchange Commission on March 9, 1999.
Registration No. 333-24361
==========================
U.S. SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
----------------------
POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-3
REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933
----------------------
GENZYME CORPORATION
(Exact name of registrant as specified in its charter)
MASSACHUSETTS 06-1047163
(State or other jurisdiction (I.R.S. Employer
of incorporation or organization) Identification Number)
ONE KENDALL SQUARE, CAMBRIDGE, MASSACHUSETTS 02139 (617) 252-7500
(Address, including zip code, and telephone number,
including area code, of registrant's principal executive offices)
----------------------
PETER WIRTH, ESQ.
Executive Vice President and Chief Legal Officer
Genzyme Corporation
One Kendall Square
Cambridge, Massachusetts 02139
(617) 252-7500
(Name, address, including zip code, and telephone number, including area code,
of agent for service)
with copies to:
PAUL M. KINSELLA, ESQ.
Palmer & Dodge LLP
One Beacon Street
Boston, Massachusetts 02108
(617) 573-0100
----------------------
Genzyme Corporation's Registration Statement on Form S-3 (File No.
333-24361) registered 2,577,245 shares of Genzyme Tissue Repair Division Common
Stock, $0.01 par value per share, issuable upon the conversion of a $13 million
convertible note. This registration statement covers resales of these shares by
the securityholder named in the prospectus. Of the 2,577,245 shares registered,
the securityholder has sold 1,318,400; the remaining 1,258,845 shares are now
eligible for sale pursuant to Rule 144. This Post-Effective Amendment is filed
to deregister the 1,258,845 unsold shares of Genzyme Tissue Repair Division
Common Stock.
<PAGE> 2
SIGNATURES
Pursuant to the requirements of the Securities Act of 1933, as amended,
the registrant certifies that it has reasonable grounds to believe that it meets
all of the requirements for filing on Form S-3 and has duly caused this
Post-Effective Amendment to be signed on its behalf by the undersigned,
thereunto duly authorized, in the City of Cambridge, Commonwealth of
Massachusetts, on March 9, 1999.
GENZYME CORPORATION
By: /s/ David J. McLachlan
--------------------------------------------
David J. McLachlan
Executive Vice President and Chief Financial
Officer
2
